Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 61Stomach Neoplasms 10HER2-positive Breast Cancer 7Colorectal Neoplasms 6Neoplasm Metastasis 5Inflammatory Breast Neoplasms 3Breast Diseases 3Brain Neoplasms 3Pathologic Complete Response 2Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cardiotoxicity 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Relapsed Pediatric Solid Tumor 1Pancreatic Neoplasms 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Invasive Breast Cancer 1Intestinal Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1HER2-positive 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Gastric Cancer 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Feasibility 1

Interventions

pertuzumab 1penpulimab 1dalpiciclib 1Trastuzumab 1Patient Reported Outcome Measures 1Induction Chemotherapy 1Fulvestrant 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasm Female × Trastuzumab × Clear all
NCT05577442 2022-10-19

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Phase 2 Unknown
52 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡